Evaluation of Myocardial Triglyceride Accumulation Assessed on ¹H-Magnetic Resonance Spectroscopy in Apparently Healthy Japanese Subjects

Eiryu Sai¹, Kazunori Shimada^{1,2}, Takayuki Yokoyama¹, Shuji Sato³, Yuji Nishizaki¹, Tetsuro Miyazaki¹, Makoto Hiki¹, Yoshifumi Tamura^{2,4}, Shigeki Aoki⁵, Hirotaka Watada^{2,4}, Ryuzo Kawamori^{2,4} and Hiroyuki Daida^{1,2}

Abstract

Objective Proton magnetic resonance spectroscopy (¹H-MRS) enables the clinician to noninvasively assess the amount of ectopic fat in the liver, skeletal muscle and myocardium. Recent studies have reported that the myocardial triglyceride (TG) content is associated with aging, metabolic disorders and cardiac dysfunction. However, the clinical usefulness of myocardial TG measurements in Japanese subjects has not been fully investigated.

Methods The myocardial TG content was evaluated using ¹H-MRS in 37 apparently healthy Japanese subjects, and the left ventricular function was measured on cardiac magnetic resonance imaging (MRI). Blood pressure, body composition and biochemical markers were measured in a fasting state, and cardiopulmonary exercise testing (CPX) was performed to evaluate exercise capacity.

Results The mean myocardial TG content was 0.85±0.40%. The myocardial TG content was significantly associated with the percent body fat (r=0.39), serum triglyceride level (r=0.40), estimated glomerular filtration rate (r=-0.37), anaerobic threshold (r=-0.36), maximal load of CPX (r=0.39), left ventricular end-diastolic volume (r=-0.41) and left ventricular end-systolic volume (LVESV) (r=-0.51) (all: p<0.05). In a multivariate analysis, the LVESV was found to be an independent factor of the myocardial TG content.

Conclusion ¹H-MRS may be useful for assessing the associations between the myocardial TG content and various clinical parameters, including those reflecting obesity, metabolic disorders, cardiac morphology and exercise capacity, noninvasively, even in Japanese subjects.

Key words: myocardial triglyceride content, magnetic resonance spectroscopy, metabolic disorders, exercise capacity

(Intern Med 54: 367-373, 2015)

(DOI: 10.2169/internalmedicine.54.3024)

Introduction

Ectopic fat is associated with obesity as well as various metabolic disorders and cardiovascular diseases (1-3). In animal studies, elevated myocardial triglyceride (TG) levels

trigger pathological changes, including myocardial apoptosis, left ventricular (LV) contractile dysfunction, LV diastolic dysfunction and LV remodeling (4, 5).

Proton magnetic resonance spectroscopy (¹H-MRS) enables the noninvasive monitoring of TG accumulation in human myocardial tissue. Previous studies have demonstrated

¹Department of Cardiology, Juntendo University Graduate School of Medicine, Japan, ²Sportology Center, Juntendo University Graduate School of Medicine, Japan, ³Department of Radiology, Juntendo University Hospital, Japan, ⁴Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Japan and ⁵Department of Radiology, Juntendo University Graduate School of Medicine, Japan

Received for publication April 4, 2014; Accepted for publication August 17, 2014

Correspondence to Dr. Kazunori Shimada, shimakaz@juntendo.ac.jp

that the myocardial TG content measured using ^1H -MRS is associated with age (6) and the presence of diabetes mellitus (7) and myocardial systolic dysfunction (4, 8, 9) or diastolic dysfunction (6, 10). In addition, progressive caloric restriction has been shown to induce a dose-dependent increase in the myocardial TG content (11), whereas endurance training reduces this parameter (12). We recently reported that the myocardial TG content is significantly lower in endurance athletes than in healthy subjects (13).

The aim of this study was to assess the associations between the myocardial TG content measured on ^1H -MRS and metabolic parameters, cardiac morphology, the left ventricular function and exercise capacity in apparently healthy Japanese subjects.

Materials and Methods

Subjects

A total of 37 apparently healthy Japanese men were recruited through a local advertisement. All subjects were 20-61 years of age and not currently receiving any medical treatment. Individuals with findings of acute or chronic diseases on a medical examination were excluded. The ethics committee of Juntendo University approved the study protocol and all subjects provided their written informed consent before participating in this study, according to the guidelines of the Declaration of Helsinki.

Measurements

Body composition was assessed in terms of skeletal muscle mass and body fat after overnight fasting using a multi-frequency bioelectrical impedance analysis with eight tactile electrodes (MF-BIA8; In-Body 720, Biospace, Seoul, Korea) (14). The subject's apparatus provides measurements of the fat mass, fat-free mass and percentage body fat. Each patient's personal activity level was assessed using the international physical activity questionnaire (IPAQ) (15).

Standard laboratory tests were performed under fasting conditions before the ^1H -MRS procedure. Serum lipid profiles were determined according to enzymatic methods, including the total cholesterol (Symex, Kobe, Japan), high-density lipoprotein (HDL) cholesterol and triglyceride (Sekisui Medical, Tokyo, Japan) levels, using a BioMajesty JCA-BM8060 analyzer (Japan Electron Optics Laboratory, Tokyo, Japan). The Friedewald formula was used to calculate the level of serum low-density lipoprotein (LDL) cholesterol. The serum insulin level was assessed using a chemiluminescent enzyme immunoassay with the Lumipulse presto II analyzer (Fujirebio, Tokyo, Japan). The homeostasis model assessment index (HOMA-IR) was calculated to estimate the degree of insulin resistance based on the fasting insulin and glucose levels, as follows: $\text{insulin } (\mu\text{U/mL}) \times \text{glucose } (\text{mmol/L})/22.5$ (16). The free fatty acid (FFA) level was measured using a standard assay (Eiken chemical, Tokyo, Japan) and BioMajesty JCA-BM2250 analyzer (Japan Elec-

tron Optics Laboratory, Tokyo, Japan). The serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level was determined using an electrostatically controlled linear inchworm actuator on modular analytics (HITACHI Hi-Technologies, Tokyo, Japan). Finally, the HbA1c level was determined in whole-blood samples according to a latex-enhanced immunoassay (Fujirebio, Tokyo, Japan).

MRI and MRS

Cardiac magnetic resonance imaging (MRI) and ^1H -MRS were conducted on a MAGNETOM Avanto 1.5-Tesla MRI system (Siemens Medical Solution, Erlangen, Germany), as previously reported (13). In brief, each subject rested in the supine position with a belt placed around the upper part of the abdomen in order to minimize respiratory movements. LV functional and morphological parameters were determined using a specially designed software program (Argus; Siemens Medical Systems, Erlangen, Germany) (17, 18) on a separate workstation. The endocardial and epicardial LV borders were traced manually on short-axis cine images obtained at end-systole and end-diastole. The LV end-diastolic volume (EDV), LV end-systolic volume (ESV), LV ejection fraction and stroke volume were calculated using Simpson's method. Furthermore, the peak LV ejection and filling rates were automatically derived from LV volume-time curves.

In order to quantify the myocardial TG content, a $10 \times 10 \times 20\text{-mm}^3$ voxel was positioned within the ventricular septum on cine dynamic cine-mode images (Fig. 1). The spectrum of water and lipids was acquired using point-resolved spectroscopy (PRESS) with a repetition time (TR) of at least 4,000 ms and echo time (TE) of 30 ms. The myocardial TG signals were acquired at 1.4 ppm from water suppressed spectra. The water signals were acquired at 4.7 ppm from non-water suppressed spectra (Fig. 1). The areas under the curves for the water and lipid peaks were quantified according to standard line-fitting procedures (Siemens Syngo Spectroscopy, Siemens Medical Solution). The myocardial TG levels are expressed as the lipid to water ratios (%) (13, 19-21).

Measurement of cardiopulmonary fitness

An incremental cycling test was performed on a Corival 400 (Lobe B.V., Groningen, Netherlands) with an expiratory gas analyzer (Vmax-295, SensorMedics, Yorba Linda, USA) in order to measure the anabolic threshold (AT) and maximal oxygen consumption ($\text{VO}_{2\text{max}}$), as previously described (22). After three minutes of rest, a three-minute warm-up test was performed at 40 W, followed by ramp loading (15-30W/min) until subjective exhaustion. According to the American Thoracic Society/American College of Chest Physicians (ATS/ACCP) guidelines, AT corresponds to the change in slope midrange of the VO_2/VCO_2 response curve (V-slope method). In cases in which the AT point was not identified on the V-slope, we used the point at which VE/VO_2 starts to increase while VE/VCO_2 remains constant, with VE corresponding to the total minute ventilation (23).

Figure 1. Representative results of the ^1H -MRS spectra in a healthy subject. A: Myocardial voxel localization for ^1H -MRS in four-chamber and short-axis views. B: ^1H -MR spectra without water suppression. C: ^1H -MR spectra without water suppression.

Table 1. Clinical Characteristics

	Total (n = 37)
Age, years	30.6 $\pm$ 8.1
Body height, m	1.728 $\pm$ 0.051
Body weight, kg	68.0 $\pm$ 6.5
Body mass index, kg/m ²	22.7 $\pm$ 2.0
Skeletal muscle mass, kg	32.9 $\pm$ 8.3
Body fat weight, kg	13.0 $\pm$ 4.4
Percent of body fat, %	18.5 $\pm$ 5.4
Neck circumference, cm	37.0 $\pm$ 2.3
Waist circumference, cm	80.0 $\pm$ 5.7
Total cholesterol, mg/dL	183 $\pm$ 29
Triglyceride, mg/dL	102 $\pm$ 73
LDL-cholesterol, mg/dL	108 $\pm$ 29
HDL-cholesterol, mg/dL	55 $\pm$ 11
Fasting free fatty acid, $\mu\text{Eq/L}$	326 $\pm$ 161
Fasting blood glucose, mg/dL	92 $\pm$ 8
Insulin, $\mu\text{U/mL}$	5.9 $\pm$ 3.7
HOMA-IR	1.3 $\pm$ 0.9
HbA1c, % (NGSP)	4.7 $\pm$ 0.2
Creatinine, mg/dL	0.83 $\pm$ 0.09
eGFR, mL/min/m ²	91.6 $\pm$ 12.4
NT-proBNP, ng/L	15.1 $\pm$ 13.3
Urinary acid, mg/L	6.0 $\pm$ 0.9
Anaerobic threshold, mL/kg/min	19.0 $\pm$ 5.2
VO ₂ max, mL/kg/min	43.2 $\pm$ 8.0
CAVI	6.5 $\pm$ 0.7
IPAQ score	2,318 $\pm$ 1,605

Values are mean $\pm$ SD. LDL: low-density lipoprotein, HDL: high-density lipoprotein, eGFR: estimated glomerular filtration rate, HOMA-IR: homeostasis model assessment of insulin resistance, NT-proBNP: N-terminal pro brain natriuretic peptides, VO₂max: maximal oxygen intake, CAVI: cardio ankle vascular index, IPAQ: international physical activity questionnaire

Table 2. MRI Variables

	Total (n = 37)
LV ejection fraction, %	50.2 $\pm$ 5.4
LV end diastolic volume, mL	157 $\pm$ 26
LV end systolic volume, mL	77 $\pm$ 16
Stroke volume, mL	80 $\pm$ 14
Cardiac output, L/min/m ²	4.9 $\pm$ 1.0
LV myocardial mass, g	124 $\pm$ 17
Peak ejection rate, mL/sec	608 $\pm$ 234
Peak filling rate, mL/sec	672 $\pm$ 251

Values are mean $\pm$ SD. LV: left ventricular

Evaluation of atherosclerotic parameters

The parameter of atherosclerosis, the cardio-ankle vascular index (CAVI), was calculated automatically using the VaSera VS-1500 AN (Fukuda Denshi, Tokyo, Japan) (24, 25).

Statistical analysis

The values are expressed as the mean $\pm$ standard deviation (SD). Variables not exhibiting a normal distribution were transformed into natural logarithmic values prior to the statistical analyses. Pearson's correlation coefficients were calculated between the myocardial TG content and the other parameters. In order to assess determinants of the myocardial TG content, we performed univariate and multivariable linear regression analyses. All statistical analyses were conducted using the SPSS version 20 software package (SPSS, Chicago, USA). A p value of less than 0.05 was considered to be statistically significant.

Figure 2. Correlations between the myocardial TG content and the clinical variables. A: Correlation between the myocardial TG content and percent body fat. B: Correlation between the myocardial TG content and the serum TG level with logarithmic transformation. C: Correlation between the myocardial TG content and estimated glomerular filtration rate.

Results

The clinical characteristics of the study subjects are summarized in Table 1. The mean age was 30.5 ± 8.1 years, the mean body mass index was 22.7 ± 2.0 kg/m² and the mean maximum VO₂ was 43.2 ± 8.0 mL/kg/min. None of the subjects were obese or had abnormal parameters on the blood analyses.

The MRI and MRS variables are shown in Table 2. None of the subjects had an abnormal ejection fraction, cardiac mass volume, peak ejection fraction or filling rate. The myocardial TG content was positively correlated with the percent body fat ($r=0.39$, $p=0.02$) and serum TG level ($r=0.35$, $p=0.001$) (Fig. 2) and negatively correlated with the estimated glomerular filtration rate (eGFR; $r=-0.37$, $p=0.02$), AT ($r=-0.36$, $p=0.02$), maximal load of cardiopulmonary exercise testing (CPX) ($r=-0.40$, $p=0.01$), left ventricular end-diastolic volume (LVEDV; $r=-0.42$, $p=0.01$) and left ventricular end-systolic volume (LVESV; $r=-0.51$, $p=0.01$) (Fig. 3). No significant correlations were noted between the myocardial TG content and the CAVI ($r=0.16$, $p=0.37$) and the IPAQ score ($r=-0.25$, $p=0.14$).

The AT level strongly correlated with the maximal CPX load ($r=0.81$, $p<0.0001$). The LVESV level also correlated with the LVEDV ($r=0.82$, $p<0.0001$). Moreover, the myocardial TG content and serum TG level were associated with insulin resistance and obesity, and the relationship between

the myocardial TG content and the eGFR was affected by aging. Therefore, we performed a multivariate analysis including age, BMI, serum TG, eGFR and LVESV. In this model, the LVESV was an independent factor of the myocardial TG content (Table 3).

Discussion

The present study demonstrated significant associations between the myocardial TG content and the percent body fat, serum TG level, eGFR, anaerobic threshold, maximal load of CPX, LVEDV and LVESV in apparently healthy Japanese subjects. In addition, the LVESV value was found to be an independent factor of the myocardial TG content.

The generation of myocardial TG is closely dependent on myocardial lipid metabolism. The accumulation of myocardial TG is primarily determined by the supply of the fatty acids and mitochondrial energy-producing efficiency (26). Moreover, myocardial lipid metabolism is regulated by a complex equilibrium between the supply of fatty acids to the heart, competing energy substrates, energy demand and supply of oxygen to the heart, uptake and esterification of fatty acids and control of the mitochondrial function (i.e. fatty acid oxidation and electron transport chain activity) (26). Therefore, it is important to assess the myocardial TG content using ¹H-MRS noninvasively in the clinical setting.

Previous studies have reported that the myocardial TG

Figure 3. Correlations between the myocardial TG content and the MRI parameters. A: Correlation between the myocardial TG content and anaerobic threshold. B: Correlation between the myocardial TG content and maximal load of cardiopulmonary exercise. C: Correlation between the myocardial TG content and left ventricular (LV) end-diastolic volume. D: Correlation between the myocardial TG content and LV end-systolic volume.

Table 3. Multivariable Linear Regression Analyses

Factors	β	p value
Age	-0.0036	0.69
BMI	0.036	0.28
Serum TG	0.00099	0.22
eGFR	-0.0070	0.22
LVESV	-0.011	0.021

BMI: body mass index, TG: triglyceride, eGFR: estimated glomerular filtration rate, LVESV: left ventricular end-systolic volume

content is related to obesity, metabolic disorders and cardiac dysfunction (1, 2, 4, 5, 7, 27). The present study confirmed an association between the myocardial TG content and parameters of metabolic disorders, including the percent body fat and serum TG levels, even in apparently healthy subjects. These associations are supported by the well-established notion that increased body fat results in insulin resistance and high TG levels. In addition, a previous study suggested that the myocardial TG content is associated with obesity via a positive association with the plasma FFA concentration (8). However, we found no correlations between the FFA level and myocardial TG content in our healthy subjects (data not shown). The present study subjects did not include obese patients or those with impaired glucose tolerance with a decreased mitochondrial function. In addition, we enrolled several healthy subjects with exercise habits. Endurance exercise regulates lipoprotein lipase synthesis

and the mitochondrial function, primarily β -oxidation (28). The background factors of the study subjects may therefore account for differences in results between the present study and previous reports.

In the current analysis, we found that morphological cardiac parameters were negatively correlated with the myocardial TG content, including the LVEDV and LVESV. In previous reports, the myocardial TG content has been shown to positively correlate with LV mass weight per LV volume according to the degree of LV hypertrophy (4). Furthermore, we recently reported that athletes exhibit lower myocardial TG levels (13). We also included several endurance athletes in the present study; however, similar trends were obtained after excluding these subjects (data not shown). Moreover, the LVESV level was found to be an independent predictor of the myocardial TG content. These data suggest that measuring the myocardial TG content is useful for assessing the relationship between cardiac remodeling and cardiac lipid metabolism, although further investigations are needed to clarify the precise mechanisms.

Finally, our data showed a negative correlation between the myocardial TG content and AT. A previous study demonstrated a negative relationship between the myocardial TG content and cardiopulmonary fitness in obese women (27). Reduced cardiorespiratory fitness predisposes to individuals to cardiovascular disease and predicts premature death (29, 30), and the level of cardiorespiratory fitness de-

depends on both the degree of obesity and age. Our next study will investigate the impact of clinical interventions on the myocardial TG content and exercise tolerance.

The present study is associated with several limitations. First, this was a single-center study with a small sample size. Second, we included only male subjects. Finally, we did not perform oral glucose tolerance tests. Therefore, some subjects with impaired glucose tolerance may have been included in our study population; however, no obese individuals or patients with impaired glucose tolerance with an obviously decreased mitochondrial function were assessed.

Conclusion

¹H-MRS may be useful for noninvasively assessing the associations between the myocardial TG content and various clinical parameters, including those indicative of obesity, metabolic disorders, cardiac morphology and exercise capacity, even in healthy Japanese subjects.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

The authors thank Tomo Onishi (Teikyo University Faculty of Medical Technology, Tokyo, Japan), Nozomi Hamasaki (Department of Radiology, Juntendo University Hospital, Tokyo, Japan), Dr. Kosuke Fukao, (Juntendo University Department of Cardiovascular Medicine Juntendo University Hospital, Tokyo, Japan) and Meang-kyu Kim (Kyungpook National University, Daegu, South Korea) for their significant support in obtaining the clinical measurements.

Financial Support

This work was partially supported by a Sportology Research Center grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a grant from the Mizuno Sports Promotion Foundation.

References

- Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. *Circulation* **124**: e837-e841, 2011.
- Iozzo P. Myocardial, perivascular, and epicardial fat. *Diabetes Care* **34** (Suppl 2): S371-S379, 2011.
- Konishi M, Sugiyama S, Sugamura K, et al. Accumulation of pericardial fat correlates with left ventricular diastolic dysfunction in patients with normal ejection fraction. *J Cardiol* **59**: 344-351, 2012.
- Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. *Magn Reson Med* **49**: 417-423, 2003.
- Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. *Proc Natl Acad Sci U S A* **97**: 1784-1789, 2000.
- van der Meer RW, Rijzewijk LJ, Diamant M, et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. *Eur Heart J* **29**: 1516-1522, 2008.
- McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a ¹H-magnetic resonance spectroscopy study. *Circulation* **116**: 1170-1175, 2007.
- Kankaanpää M, Lehto HR, Parkka JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. *J Clin Endocrinol Metab* **91**: 4689-4695, 2006.
- Unger RH. The physiology of cellular liporegulation. *Annu Rev Physiol* **65**: 333-347, 2003.
- Christoffersen C, Bollano E, Lindegaard ML, et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. *Endocrinology* **144**: 3483-3490, 2003.
- Hammer S, van der Meer RW, Lamb HJ, et al. Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. *J Clin Endocrinol Metab* **93**: 497-503, 2008.
- Schrauwen-Hinderling VB, Hesselink MK, Meex R, et al. Improved ejection fraction after exercise training in obesity is accompanied by reduced cardiac lipid content. *J Clin Endocrinol Metab* **95**: 1932-1938, 2010.
- Sai E, Shimada K, Yokoyama T, et al. Association between myocardial triglyceride content and cardiac function in healthy subjects and endurance athletes. *PloS One* **8**: e61604, 2013.
- Gibson AL, Holmes JC, Desautels RL, Edmonds LB, Nuudi L. Ability of new octapolar bioimpedance spectroscopy analyzers to predict 4-component-model percentage body fat in Hispanic, black, and white adults. *Am J Clin Nutr* **87**: 332-338, 2008.
- Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* **35**: 1381-1395, 2003.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **28**: 412-419, 1985.
- Chai JW, Chen WH, Chen HM, et al. Correction of left ventricular wall thickening from short-axis cine MRI for basal-descent through-plane motion. *J Magn Reson Imaging* **33**: 464-473, 2011.
- Gandy SJ, Waugh SA, Nicholas RS, Simpson HJ, Milne W, Houston JG. Comparison of the reproducibility of quantitative cardiac left ventricular assessments in healthy volunteers using different MRI scanners: a multicenter simulation. *J Magn Reson Imaging* **28**: 359-365, 2008.
- den Hollander JA, Evanochko WT, Pohost GM. Observation of cardiac lipids in humans by localized ¹H magnetic resonance spectroscopic imaging. *Magn Reson Med* **32**: 175-180, 1994.
- Feliblinger J, Jung B, Slotboom J, Boesch C, Kreis R. Methods and reproducibility of cardiac/respiratory double-triggered (1) H-MR spectroscopy of the human heart. *Magn Reson Med* **42**: 903-910, 1999.
- McBavock JM, Victor RG, Unger RH, Szczepaniak LS, American College of Physicians and the American Physiological Society. Adiposity of the heart, revisited. *Ann Intern Med* **144**: 517-524, 2006.
- Nishitani M, Shimada K, Sunayama S, et al. Impact of diabetes on muscle mass, muscle strength, and exercise tolerance in patients after coronary artery bypass grafting. *J Cardiol* **58**: 173-180, 2011.
- American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* **167**: 211-277, 2003.
- Oleinikov VE, Matrosova IB, Sergatskaia NV, Tomashevskaja IA. The diagnostic value and clinical significance of a method for estimating the arterial stiffness by cardio-ankle vascular index. *Ter Arkh* **82**: 68-72, 2010.
- Satoh N, Shimatsu A, Kato Y, et al. Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. *Hypertens Res* **31**: 1921-1930, 2008.
- Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC.

- Myocardial fatty acid metabolism in health and disease. *Physiol Rev* **90**: 207-258, 2010.
27. Utz W, Engeli S, Haufe S, et al. Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obese women. *Heart* **97**: 1585-1589, 2011.
28. Roth SM, Rankinen T, Hagberg JM, et al. Advances in exercise, fitness, and performance genomics in 2011. *Med Sci Sports Exerc* **44**: 809-817, 2012.
29. Carnethon MR, Gulati M, Greenland P. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. *JAMA* **294**: 2981-2988, 2005.
30. Sui X, LaMonte MJ, Laditka JN, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. *JAMA* **298**: 2507-2516, 2007.